Search research articles
Contact Us
Filters
Showing results (21-30 of 58) with videos related to
Page
of 6
Sort By:
Metabolism: Clinical and Experimental
|
March 9, 2010
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone
Alessandro Antonelli, Silvia Martina Ferrari, Poupak Fallahi, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 10, 2015
Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy
Danila Covelli, Guia Vannucchi, Irene Campi, et al.
European Journal of Endocrinology
|
October 17, 2013
The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor
Guia Vannucchi, Danila Covelli, Irene Campi, et al.
Investigative Ophthalmology & Visual Science
|
May 4, 2010
Corneal involvement in Graves' orbitopathy: an in vivo confocal study
Edoardo Villani, Francesco Viola, Roberto Sala, et al.
Reviews in Endocrine & Metabolic Disorders
|
February 16, 2026
The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease
Daniel G Ezra, Atsushi Azumi, César A Briceño, et al.
European Thyroid Journal
|
April 22, 2016
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy
Luigi Bartalena, Lelio Baldeschi, Kostas Boboridis, et al.
European Thyroid Journal
|
March 12, 2024
Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab
Ilaria Muller, Sara Maioli, Mirco Armenti, et al.
Thyroid : Official Journal of the American Thyroid Association
|
December 21, 2019
Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study
Guia Vannucchi, Danila Covelli, Irene Campi, et al.
European Thyroid Journal
|
December 8, 2022
Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association
Henry B Burch, Petros Perros, Tomasz Bednarczuk, et al.
Thyroid : Official Journal of the American Thyroid Association
|
December 8, 2022
Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association
Henry B Burch, Petros Perros, Tomasz Bednarczuk, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 58) with videos related to
Sort By:
Page
of 6
Metabolism: Clinical and Experimental
|
March 9, 2010
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone
Alessandro Antonelli, Silvia Martina Ferrari, Poupak Fallahi, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 10, 2015
Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy
Danila Covelli, Guia Vannucchi, Irene Campi, et al.
European Journal of Endocrinology
|
October 17, 2013
The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor
Guia Vannucchi, Danila Covelli, Irene Campi, et al.
Investigative Ophthalmology & Visual Science
|
May 4, 2010
Corneal involvement in Graves' orbitopathy: an in vivo confocal study
Edoardo Villani, Francesco Viola, Roberto Sala, et al.
Reviews in Endocrine & Metabolic Disorders
|
February 16, 2026
The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease
Daniel G Ezra, Atsushi Azumi, César A Briceño, et al.
European Thyroid Journal
|
April 22, 2016
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy
Luigi Bartalena, Lelio Baldeschi, Kostas Boboridis, et al.
European Thyroid Journal
|
March 12, 2024
Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab
Ilaria Muller, Sara Maioli, Mirco Armenti, et al.
Thyroid : Official Journal of the American Thyroid Association
|
December 21, 2019
Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study
Guia Vannucchi, Danila Covelli, Irene Campi, et al.
European Thyroid Journal
|
December 8, 2022
Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association
Henry B Burch, Petros Perros, Tomasz Bednarczuk, et al.
Thyroid : Official Journal of the American Thyroid Association
|
December 8, 2022
Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association
Henry B Burch, Petros Perros, Tomasz Bednarczuk, et al.
Page
of 6